Clinical Trials Browser

Phase 2 × INDUSTRY × atezolizumab × Clear all

NCT04302025 2026-05-22

NAUTIKA1

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07235293 2026-05-22

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07155174 2026-05-18

SEZanne

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05968326 2026-05-11

IMCODE003

Phase 2 Recruiting

Adenocarcinoma

NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Phase 2 Active not recruiting

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT04665843 2026-05-05

SKYSCRAPER-09

Phase 2 Completed

123 enrolled 22 charts

Squamous Cell Carcinoma of Head and Neck

NCT03563716 2026-05-04

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2 Completed

135 enrolled 19 charts

Carcinoma, Non-Small-Cell Lung

NCT06096779 2026-05-04

Kirros

Phase 2 Recruiting

Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT06390059 2026-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT05645692 2026-04-29

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Phase 2 Active not recruiting

Urothelial Cancer

NCT05009069 2026-04-21

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT04300647 2026-03-12

SKYSCRAPER-04

Phase 2 Completed

172 enrolled 27 charts

Uterine Cervical Neoplasms

NCT04832854 2026-03-11

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Phase 2 Terminated

50 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT04931342 2026-03-10

BOUQUET

Phase 2 Active not recruiting

Ovarian Neoplasms

NCT05733611 2026-02-02

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04770272 2026-01-12

neoMono

Phase 2 Terminated

442 enrolled 42 charts

Triple Negative Breast Neoplasms

NCT00781612 2025-12-24

A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT05171777 2025-12-11

A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer

Phase 2 Completed

179 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT06463665 2025-09-26

VIRO-25

Phase 2 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

NCT03041311 2025-09-25

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Phase 2 Completed

107 enrolled 42 charts

Small Cell Lung Carcinoma

NCT05243862 2025-03-18

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT04632992 2025-01-08

MyTACTIC

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT06331598 2024-12-24

IMperator

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumors

NCT04933227 2024-11-14

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT04091217 2024-10-24

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Phase 2 Completed

43 enrolled 12 charts

Melanoma

NCT06099418 2024-09-20

Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Phase 2 Withdrawn

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT02927301 2024-09-19

A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

Phase 2 Completed

181 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT04622228 2024-07-29

Match

Phase 2 Completed

Small Cell Lung Carcinoma

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Phase 2 Completed

673 enrolled 22 charts

GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT04677504 2024-07-03

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Phase 2 Completed

162 enrolled 18 charts

Gastrointestinal

Biliary Tract Neoplasms

NCT04321330 2024-06-11

A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma

Phase 2 Completed

Thymoma

NCT04426825 2024-05-21

A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Completed

23 enrolled 23 charts

Carcinoma, Non-Small-Cell Lung

NCT02291289 2024-05-06

MODUL

Phase 2 Completed

1,044 enrolled 21 charts

Gastrointestinal

Colorectal Neoplasms

NCT03625141 2024-04-11

A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases

Phase 2 Completed

80 enrolled 20 charts

Melanoma

NCT02108652 2024-03-28

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)

Phase 2 Completed

310 enrolled 23 charts

Urinary Bladder Neoplasms

NCT02951767 2024-03-28

A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

Phase 2 Completed

119 enrolled 18 charts

Urinary Bladder Neoplasms

NCT04984811 2024-03-05

NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT04405349 2023-12-15

Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms, Neoplasm Metastasis, Recurrence

NCT04308785 2023-10-23

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Phase 2 Terminated

Small Cell Lung Carcinoma

NCT03961698 2023-08-14

MARIO-3

Phase 2 Unknown

BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell, Triple Negative Breast Neoplasms

NCT02322814 2023-04-13

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Phase 2 Terminated

169 enrolled 31 charts

Breast Neoplasms

NCT03073525 2023-04-05

A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers

Phase 2 Completed

25 enrolled 15 charts

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms

NCT03386721 2023-02-21

Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors

Phase 2 Terminated

256 enrolled 26 charts

Uterine Cervical Neoplasms

NCT03628716 2022-04-27

CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Phase 2 Completed

43 enrolled 21 charts

Urinary Bladder Neoplasms